TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05127226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION582
Description: ION582 will be administered by IT injection.
Study: NCT05857436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apical periodontitis
Description: Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apical periodontitis
Description: Of these patients, 60 patients with AP and extraction indication (due to restorative causes and lesion size) were included in the study
Study: NCT06475508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Complarate®
Description: The investigational drug Complarate® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actemra®
Description: The reference drug Actemra® was administered as an intravenous infusion at a dose of 8 mg/kg once every 4 weeks for 24 weeks.
Study: NCT05752916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Agents
Description: Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
Study: NCT05602402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAEP-01
Description: Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
Study: NCT06125132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with-tooth colored material
Description: Restoration of abrasions with different composite resin materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with-tooth colored material
Description: Restoration of abrasions with different composite resin materials

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with-tooth colored material
Description: Restoration of abrasions with different composite resin materials
Study: NCT05814991

Intervention type: DRUG
Intervention: Nitroglycerin solution
Description: Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.

Intervention type: DEVICE
Intervention: monitoring of cerebral oxygen saturation
Description: NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
Study: NCT06233357

Intervention type: DRUG
Intervention: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
Description: IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight

Intervention type: DRUG
Intervention: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
Description: IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight

Intervention type: DRUG
Intervention: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
Description: IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
Study: NCT05499039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Description: High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Description: High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C Flow rate 30: 50 L/min. FiO2 will be adjusted to achieve a SpO2 at least 95%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Mechanical Ventilation (NIV)
Description: Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Mechanical Ventilation (NIV)
Description: Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O. Pressure support (PS): 12-20 cmH2O. FiO2 will be adjusted to achieve a SpO2 at least 95% Intervention: Device: non-invasive ventilation
Study: NCT05950841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IHAT
Description: Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose IHAT
Description: Twice daily dose of 1 capsule (100mg per capsule IHAT)
Study: NCT05775744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight postpartum blood pressure control
Description: The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
Study: NCT06520319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-MGS5
Description: Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
Study: NCT05950841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carob flour
Description: Twice daily dose of 1 capsule (carob flour)
Study: NCT06107582

Intervention type: OTHER
Intervention: data collection
Description: The study will collect basic information, diagnostic and treatment information from medical records and use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Study: NCT04666506

Intervention type: OTHER
Intervention: Virtual reality
Description: The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog).

Intervention type: OTHER
Intervention: Virtual reality
Description: The VR intervention, Relaxation-VR, is a VR application developed by Psylaris aiming to reduce anxiety/stress and pain by distracting the patient in a relaxing environment. Relaxation-VR will be administered via a commercially available VR headset (Oculus Go). The VR headset is a piece of equipment that a person wears over their eyes that allows them to experience images and sounds produced by a computer as if they were part of real life (Cambridge Dictionary, 2020). As such, the patient is immersed in a novel, calming and distracting environment where the he/she is asked to perform tasks that will help the patients to relax when distressed before and/or during a medical procedure or during their stay in hospital.~The Relaxation-VR application consists of three modules: two modules make use of relaxation principles (i.e. breathing exercises, meditation) and one module presents a scene with different interactive animations and objects (i.e. popping bubbles, playing fetch with a dog).
Study: NCT05335798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodyweight augment system
Description: Motorized cables will be providing downward force on the participant's pelvis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart insole
Description: Insole provided auditory feedback when heel strike or toe-off events happen
Study: NCT04753580

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: The volunteer will receive the stool collection kit as well as the procedure to follow for this collection.~Treatment of stool after collection:~The stool will be treated according to the following two procedures:~i) part of the stool will be sequenced and will be stored as quickly as possible (4 hours maximum) at -80 ° C, 3 separate aliquots of 1 g; ii) the other part will be intended for implantation in rats and must be homogenized in a final concentration of 20% glycerol (2 hours maximum) and then stored at -80 ° C, 3 aliquots of 1 g.
Study: NCT05433935

Intervention type: OTHER
Intervention: Observation
Description: This is an observational study.
Study: NCT05740657

Intervention type: DRUG
Intervention: Fentanyl
Description: The drugs were administered in the course of a surgery or for pain management.
Study: NCT05254769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback Equipment (Cygnet) by BEE Medic GmbH Technologies, Baden-Wurttemberg, Germany.
Description: The EEG NeuroAmp (Electroencephalogram Amplifier) is a user-friendly high-performance interface between client and clinician computer. It can be used in two different functionalities: In an EEG/ERP (Event related potential) measurement and in an EEG biofeedback (neurofeedback) and/or peripheral biofeedback setting.
Study: NCT05308381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted exercise
Description: Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein breakfast exercise
Description: Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast exercise
Description: Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
Study: NCT05344326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy - Guided Self Help (CAT-GSH)
Description: CAT-GSH is a novel intervention designed to help those with depression by focusing on the relationships within their life. GSH is used in step two of IAPT services and is typically six fortnightly sessions where the PWP helps the service user complete the self help manual.
Study: NCT05495477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT
Description: Evaluation of ventilation distrinution during deep sedation through EIT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT
Description: Evaluation of ventilation distrinution during deep sedation through EIT
Study: NCT06149182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life stress interview according to EAET
Description: This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric interview according to region stockholm - basutredning
Description: This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
Study: NCT05111067

Intervention type: GENETIC
Intervention: DNA and whole transcriptome mRNA sequencing
Description: DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).

Intervention type: GENETIC
Intervention: DNA and whole transcriptome mRNA sequencing
Description: DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
Study: NCT05041829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary sodium
Description: Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Description: Low sodium diet with sodium of \<2.3 g/day (\<100 mmol/day) and high sodium diet with sodium of ≥4 - \<6 g/day (≥174 - \<261 mmo/day)
Study: NCT06489925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: The Cerebrolysin will be administered at least one hour after the standard treatment and no later than 24 hours after the stroke symptom onset.
Study: NCT05495477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT
Description: Evaluation of ventilation distrinution during deep sedation through EIT
Study: NCT05313490

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 7 days of 140 mL per day of beetroot juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beetroot Juice
Description: 7 days of 140 mL per day of placebo beetroot juice
Study: NCT06206590

Intervention type: OTHER
Intervention: Whole-proteomic assay
Description: Whole-proteomic analysis was performed on all the blood samples

Intervention type: OTHER
Intervention: Whole-proteomic assay
Description: Whole-proteomic analysis was performed on all the blood samples
Study: NCT03956160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.
Description: 4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures.
Study: NCT06169046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study: NCT06460389

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity Assessment
Description: Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity Assessment
Description: Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
Study: NCT05765396

Intervention type: DEVICE
Intervention: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Description: The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.

Intervention type: DEVICE
Intervention: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Description: The imPulse™ Systems are an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.
Study: NCT05802108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab combined with statins
Description: The experimental group was treated with evolocumab combined with statin for lipid-lowering

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: the control group was treated with statin only for lipid-lowering
Study: NCT06448598

Intervention type: OTHER
Intervention: Exercise
Description: The exercise protocol involved twice-weekly sessions, with aerobic exercises performed at 70% of the maximum heart rate achieved during the step test, and resistance exercises at 60% of 1RM. Participants self-selected their exercise timing, either intradialytic (during HDF sessions) or interdialytic (on non-dialysis days). For the intradialytic group, exercise was seamlessly integrated into the HDF session, excluding the initial and final two hours of dialysis.
Study: NCT06376383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Standard tonsillectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Description: Tonsillotomy
Study: NCT05795114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program
Description: A 5-part interpersonal therapy based intervention
Study: NCT06348407

Intervention type: DRUG
Intervention: IgE monoclonal antibody
Description: omalizumab

Intervention type: DRUG
Intervention: IgE monoclonal antibody
Description: omalizumab

Intervention type: DRUG
Intervention: IgE monoclonal antibody
Description: omalizumab